https://doi.org/10.4081/qrmh.2020.9564
It’s long-term, well it’s for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders
Published: 25 February 2021
Abstract Views: 898
PDF: 353
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
This paper describes the burden of receiving immunoglobulin (Ig) treatment from the perspective of patients diagnosed with a Primary Immunodeficiency (PID). Thirty semi-structured interviews with patients receiving intravenous (n=21) and subcutaneous immunoglobulin (n=9) therapy, either at home or in hospital were undertaken. Underpinned by a phenomenological theoretical framework, and using a qualitative, inductive thematic approach to prioritise patients’ concerns, we identified that Ig treatment requires considerable effort by the patient, particularly in relation to the amount of time, organization and planning that is needed. They also face numerous physical, social, relationship, emotional, role functioning, travelling, and financial challenges in their effort to undergo and maintain their infusions and care for their health. Some qualitative differences in treatment burden were noted between home and hospital settings which contributed to non-adherence to those regimes. Immunoglobulin treatment burden is complex and influenced by therapeutic mode and setting and the personal circumstances of the patient. As choice over treatment method appears to be mainly informed by lifestyle needs, PID patients may benefit from more information about these potential Ig lifestyle influences when selecting which form of treatment to take together with their health professional.
Espanol T, Prevot J, Drabwell J, et al. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adherence 2014;8:621-9.
DOI: https://doi.org/10.2147/PPA.S60771
Mozaffari H, Pourpak Z, Pourseyed S, et al. Health-related quality of life in primary immune deficient patients. Iran J Allergy Asthma Immunol 2006;5:23-7.
UK P. What are PIDs? The basics. Accessed: 18th February. Available from: http://www.piduk.org/whatarepids/basics
Ataeinia B, Montazeri A, Tavakol M, et al. Measurement of Health-Related Quality of Life in Primary Antibody-Deficient Patients. Immunol Invest 2017;46:329-40.
DOI: https://doi.org/10.1080/08820139.2016.1258710
Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006;6:434-42.
DOI: https://doi.org/10.1097/01.all.0000246619.49494.41
Jolles S, Orange JS, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol 2015;179:146-60.
DOI: https://doi.org/10.1111/cei.12485
Tran VT, Montori VM, Eton DT, et al. Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions. BMC Medicine 2012;10:68.
DOI: https://doi.org/10.1186/1741-7015-10-68
May CR, Eton DT, Boehmer K, et al. Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness. BMC Health Serv Res 2014;14:281.
DOI: https://doi.org/10.1186/1472-6963-14-281
Sav A, Kendall E, McMillan SS, et al. 'You say treatment, I say hard work': treatment burden among people with chronic illness and their carers in Australia. Health Soc Care Community 2013;21:665-74.
DOI: https://doi.org/10.1111/hsc.12052
Mair FS, May CR. Thinking about the burden of treatment. BMJ 2014;349:g6680.
DOI: https://doi.org/10.1136/bmj.g6680
Brod M, Hammer M, Christensen T, et al. Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device). Health and Quality of Life Outcomes 2009;7:83.
DOI: https://doi.org/10.1186/1477-7525-7-83
Pifferi M, Bush A, Di Cicco M, et al. Health-related quality of life and unmet needs in patients with primary ciliary dyskinesia. Eur Respir J 2010;35:787-94.
DOI: https://doi.org/10.1183/09031936.00051509
Daly PB, Evans JH, Kobayashi RH, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy 1991;67:504-10.
Howard V, Greene JM, Pahwa S, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol 2006;118:201-8.
DOI: https://doi.org/10.1016/j.clim.2005.11.002
Gardulf A, Bjorvell H, Andersen V, et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995;21:917-27.
DOI: https://doi.org/10.1046/j.1365-2648.1995.21050917.x
Nicolay U, Haag S, Eichmann F, et al. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res 2005;14:1683-91.
DOI: https://doi.org/10.1007/s11136-005-1746-x
Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004;114:936-42.
DOI: https://doi.org/10.1016/j.jaci.2004.06.053
Jones CA, Rojavin M, Baggish JS. Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety. J Pharmaceut Health Serv Res 2012;3:41-7.
DOI: https://doi.org/10.1111/j.1759-8893.2011.00076.x
Gardulf A, Bjorvell H, Gustafson R, et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993;92:200-4.
DOI: https://doi.org/10.1111/j.1365-2249.1993.tb03380.x
Vultaggio A, Azzari C, Milito C, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig 2015;35:179-85.
DOI: https://doi.org/10.1007/s40261-015-0270-1
Gardulf A, Borte M, Ochs HD, Nicolay U. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008;126:81-8.
DOI: https://doi.org/10.1016/j.clim.2007.06.009
Beauté J, Levy P, Millet V, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol 2010;160:240-5.
DOI: https://doi.org/10.1111/j.1365-2249.2009.04079.x
Jones GL, Vogt KS, Chambers D, et al. What is the burden of immunoglobulin replacement therapy in adult patients with primary immunodeficiencies? A Systematic Review. Front Immunol 2018;9:1308.
DOI: https://doi.org/10.3389/fimmu.2018.01308
Eton DT, Ramalho de Oliveira D, Egginton JS, et al. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat Outcome Meas 2012;3:39-49.
DOI: https://doi.org/10.2147/PROM.S34681
Petersson C, Fust R, Hagstedt C, et al. "Experiences of the burden of treatment"-Patient reports of facilitated subcutaneous immunoglobulin treatment in adults with immunodeficiency. J Clin Nurs 2018;27:4270-8.
DOI: https://doi.org/10.1111/jocn.14580
Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Quality Quantity 2018;52:1893-907.
DOI: https://doi.org/10.1007/s11135-017-0574-8
Lincoln Y, Guba E. Naturalistic Inquiry. Newbury Park, CA: Sage Publications; 1985.
DOI: https://doi.org/10.1016/0147-1767(85)90062-8
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77-101.
DOI: https://doi.org/10.1191/1478088706qp063oa
Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. Nurs Health Sci 2013;15:398-405.
DOI: https://doi.org/10.1111/nhs.12048
Friese S. Qualitative Data Analysis with ATLAS.ti: SAGE Publications Limited; 2019.
Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013;27:171-8.
DOI: https://doi.org/10.1016/j.tmrv.2013.05.004
Chapel H, Prevot J, Gaspar HB, et al. Primary immune deficiencies - principles of care. Front Immunol. 2014;5:627.
DOI: https://doi.org/10.3389/fimmu.2014.00627
Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 2012;32:1180-92.
DOI: https://doi.org/10.1007/s10875-012-9720-1
Eton DT, Yost KJ, Lai JS, et al. Development and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden. Qual Life Res 2017;26:489-503.
DOI: https://doi.org/10.1007/s11136-016-1397-0
Potter J, Hepburn A. Qualitative interviews in psychology: problems and possibilities. Qual Res Psychol 2005;2:281-307.
DOI: https://doi.org/10.1191/1478088705qp045oa
May C, Montori VM, Mair FS. We need minimally disruptive medicine. BMJ 2009;339:b2803.
DOI: https://doi.org/10.1136/bmj.b2803
Sheehan OC, Leff B, Ritchie CS, et al. A systematic literature review of the assessment of treatment burden experienced by patients and their caregivers. BMC Geriatr 2019;19:262.
DOI: https://doi.org/10.1186/s12877-019-1222-z
Lamb CC, Wang Y, Lyytinen K. Shared decision making: Does a physician's decision-making style affect patient participation in treatment choices for primary immunodeficiency? J Eval Clin Pract 2019;25:1102-10.
DOI: https://doi.org/10.1111/jep.13162
Jones GL, Williams K, Edmondson-Jones M, et al. The Development of a New Questionnaire to Measure the Burden of Immunoglobulin Treatment in Patients with Primary Immunodeficiencies: The IgBoT-35. Patient Prefer Adherence 2020;14:1567-84
DOI: https://doi.org/10.2147/PPA.S234669
Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Food and Drug Administration. U.S. Department of Health and Human Services; 2009.
How to Cite
Jones, Georgina, Eva Brown Hajdukova, Esmee Hanna, Rosie Duncan, Brendan Gough, Jane Hughes, Debbie Hughes, Fran Ashworth, Johan Prevot, Jose Drabwell, Leire Solis, Nizar Mahlaoui, and Anna Shrimpton. 2021. “It’s Long-Term, Well it’s for Life Basically: Understanding and Exploring the Burden of Immunoglobulin Treatment in Patients With Primary Immunodeficiency Disorders”. Qualitative Research in Medicine and Healthcare 4 (3). https://doi.org/10.4081/qrmh.2020.9564.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.